The Institute of Bioorganic Chemistry offers consumers the antireflux antacid agent AlginoMAX / AlginoMAX under a manufacturing agreement and is looking for partners to conclude a distribution services agreement.

The Institute of Bioorganic Chemistry has developed and manufactures the antireflux antacid agent AlginoMAX / AlginoMAX for the treatment of peptic ulcers of various origins and gastroesophageal reflux disease (acid regurgitation, irritation of the esophageal mucosa, and other symptoms of dyspepsia).

The antireflux antacid agent AlginoMAX / AlginoMAX has high therapeutic efficiency due to the ability to form a physical barrier in the form of a raft between the stomach's acidic contents and the esophageal mucosa. Does not significantly affect the mechanisms of production of hydrochloric acid in the stomach and the digestion process.

Patent RB No. 17792 "Pharmaceutical composition as a substance of an antireflux antacid preparation".

The Institute carries out a significant amount of fundamental research under the grants of the Belarusian Republican Foundation for Fundamental Research, including with the participation of international partners - organizations from Russia, the Czech Republic, etc.

Consumers interested in purchasing the antireflux antacid agent AlginoMAX / AlginoMAX under a manufacturing agreement.

Distributors interested in purchasing the antireflux antacid agent AlginoMAX / AlginoMAX under a distribution services agreement.